FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+31.43%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$542M
AUM Growth
+$542M
(+24%)
Cap. Flow
+$39.1M
Cap. Flow
% of AUM
7.22%
Top 10 Holdings %
Top 10 Hldgs %
68.16%
Holding
28
New
1
Increased
9
Reduced
4
Closed
2
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$42.6M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$17.9M |
| 3 |
Terns Pharmaceuticals
TERN
|
$12.1M |
| 4 |
Viridian Therapeutics
VRDN
|
$8.73M |
| 5 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$7.73M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$30.5M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$13.4M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$10.1M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$8.99M |
| 5 |
Olema Pharmaceuticals
OLMA
|
$3.97M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$6.05B
| $84.6M | 14.88% |
1,896,647
+954,076
| +101% | +$42.6M |
|
2
Cogent Biosciences
COGT
$1.69B
| $41.2M | 7.24% |
2,758,975
| – | – |
|
3
Nuvalent
NUVL
$5.52B
| $40.4M | 7.11% |
2,079,863
+364,345
| +21% | +$7.08M |
|
|
4
BioCryst Pharmaceuticals
BCRX
$1.74B
| $32M | 5.63% |
2,543,107
-800,000
| -24% | -$10.1M |
|
|
BHVN
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $31M | 5.44% |
204,743
-59,463
| -23% | -$8.99M |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $30.1M | 5.28% |
283,000
| – | – |
|
7
Insmed
INSM
$28.8B
| $28.8M | 5.06% |
1,336,368
+10,000
| +0.8% | +$215K |
|
|
8
Viridian Therapeutics
VRDN
$1.5B
| $28.1M | 4.94% |
1,369,623
+425,531
| +45% | +$8.73M |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $27.4M | 4.81% |
2,678,982
+1,752,380
| +189% | +$17.9M |
|
10
argenx
ARGX
$43.6B
| $26M | 4.56% |
73,526
| – | – |
|
11
Enanta Pharmaceuticals
ENTA
$180M
| $24.3M | 4.28% |
469,264
| – | – |
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $21.9M | 3.85% |
2,833,950
+1,000,000
| +55% | +$7.73M |
|
13
Annexon
ANNX
$226M
| $20.8M | 3.65% |
3,358,563
+465,963
| +16% | +$2.88M |
|
|
DBVT
14
DBV Technologies
DBVT
$264M
| $12.5M | 2.2% |
7,064,964
+2,233,809
| +46% | +$3.95M |
|
15
Tyra Biosciences
TYRA
$675M
| $12.5M | 2.19% |
1,416,998
| – | – |
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $12.3M | 2.16% |
751,804
| – | – |
|
|
17
Terns Pharmaceuticals
TERN
$609M
| $12.1M | 2.12% |
+2,050,000
| New | +$12.1M |
|
|
ONC
18
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $11.6M | 2.05% |
86,400
-25,000
| -22% | -$3.37M |
|
19
Keros Therapeutics
KROS
$618M
| $10.3M | 1.8% |
272,498
| – | – |
|
20
Trevi Therapeutics
TRVI
$883M
| $8.77M | 1.54% |
5,696,515
+4,072,126
| +251% | +$6.27M |
|
21
Astria Therapeutics
ATXS
$349M
| $8.24M | 1.45% |
911,736
| – | – |
|
|
AMRN
22
Amarin Corp
AMRN
$311M
| $6.09M | 1.07% |
5,584,837
| – | – |
|
23
Iovance Biotherapeutics
IOVA
$807M
| $3.73M | 0.66% |
389,588
| – | – |
|
|
24
Olema Pharmaceuticals
OLMA
$375M
| $3.4M | 0.6% |
1,231,566
-1,437,734
| -54% | -$3.97M |
|
25
Instil Bio
TIL
$182M
| $3.26M | 0.57% |
673,905
| – | – |
|